Hydrocodone

Phase 2Small molecule

MM.D. Anderson Cancer Center

Hydrocodone is one of 75 small molecule programs targeting Nausea and vomiting. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nausea and VomitingActive, not recruiting

Back PainActive, not recruiting

Opioid ConsumptionRecruiting

Nausea and VomitingPreclinical

Active, not recruiting

Back PainPreclinical

Active, not recruiting

Opioid ConsumptionPhase 2

Recruiting

Competition

Competitive Landscape

78 competitors in Nausea and Vomiting

#DrugCompanyPhaseTrials

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

38 2

Duragesic

CCephalon

Approved

1 3

Xylocaine

MMEDRx USA, Inc.

Approved

1 4

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 5

Thalomid

Bristol-Myers Squibb

Phase 3

2 6

Abraxane

Bristol-Myers Squibb

Phase 3

1 7

Gemzar

Johnson & Johnson

Phase 3

1 8

Megace

Bristol-Myers Squibb

Phase 3

1 9

Nereus

VVanda Pharmaceuticals

Phase 3

2 10

HSK21542

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Opioid Consumption

NCT06780202

Q3 2028

Recruiting

Lactating Women on Select DOI

NCT03511118

Clinical

Trials by Indication[1]

Back pain1 trial

Battlefield Acupuncture for Acute/Subacute Back Pain in the Emergency Department

Completed·SSan Antonio Military Medical Center·N/A·NCT03996564·26 enrolled

Third Molar1 trial

Controlled Trial to Determine Most Effective Post-Operative Analgesia After Third Molar Extraction

Completed·UUnited States Naval Medical Center, San Diego·Phase 1·NCT06484439·80 enrolled

Age1 trial

Bandage Contact Lenses for Corneal Abrasions

Unknown status·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 2·NCT03206723·60 enrolled

Single Dose1 trial

Single Dose Pharmacokinetics of Egalet® Hydrocodone

Completed·EEgalet Ltd·Phase 1·NCT00802087·28 enrolled

Buprenorphine1 trial

Analgesic Response to Opioid Analgesics in Buprenorphine-Maintained Individuals

Unknown status·UUniversity of California, Los Angeles·N/A·NCT02136784·12 enrolled

8 more indications

Cancer1 trial

Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT03579446·43 enrolled

Chronic pain1 trial

Pharmacokinetic Study of Hydrocodone/APAP in Chronic Pain Patients

Completed·NNEMA Research, Inc.·Phase 4·NCT01517295·30 enrolled

Emergency Department Patient1 trial

Emergency Department (ED) Drug Interaction in Emergency Department Patients

Completed·UUniversity of Colorado, Denver·N/A·NCT01859715·502 enrolled

Opioid Consumption1 trial

Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients

Recruiting·EEmory University·Phase 2·NCT06780202·180 enrolled

Nausea and vomiting1 trial

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

Completed·VVanderbilt University·N/A·NCT02625181·27,034 enrolled

Intra-abdominal Cancer1 trial

5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT06232577·165 enrolled

Lactating Women on Select DOI1 trial

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Recruiting·DDuke University··NCT03511118·1,600 enrolled

Pain Management1 trial

Comparing the Efficacy of Oral Opioids for Outpatient Acute Pain Management After ED Discharge

Completed·MMontefiore Medical Center·Phase 3·NCT01402375·720 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Hydrocodone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hydrocodone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hydrocodone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MM.D. Anderson Cancer Center

Hydrocodone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2028

Trials by Indication[1]

Back pain1 trial

Third Molar1 trial

Age1 trial

Single Dose1 trial

Buprenorphine1 trial

Cancer1 trial

Chronic pain1 trial

Emergency Department Patient1 trial

Opioid Consumption1 trial

Nausea and vomiting1 trial

Intra-abdominal Cancer1 trial

Lactating Women on Select DOI1 trial

Pain Management1 trial

References

Drug Info

Quick Facts

Related News